Insitro takes a data-first approach to drug discovery, combining machine learning with high-throughput biology to find treatments that have a better shot at actually working in humans. The company was founded on a core insight: most drugs fail in clinical trials because the disease models used during discovery don’t accurately reflect human biology.
To fix this, Insitro generates massive datasets from human-derived cell systems, including induced pluripotent stem cells (iPSCs) that can be programmed to become virtually any cell type. They pair these biological systems with CRISPR gene editing, automated laboratories, and advanced imaging to create detailed maps of how diseases work at the cellular level.
Founded by Daphne Koller — a Stanford professor, MacArthur Fellow, and co-founder of Coursera — Insitro has attracted top talent from both machine learning and biology. The company has raised over $700 million from investors including Andreessen Horowitz, GV, and T. Rowe Price.
Insitro’s pipeline focuses on metabolic diseases and neuroscience, areas where traditional drug discovery has struggled particularly hard. Their partnership with Bristol Myers Squibb on ALS and frontotemporal dementia is worth up to $2 billion in milestones. The company’s bet is that better data and smarter models upstream will translate into higher clinical trial success rates downstream — addressing the pharmaceutical industry’s most expensive problem.
